These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 24839807)
1. Appropriate management of molecular subtypes of diffuse large B-cell lymphoma. Dunleavy K; Wilson WH Oncology (Williston Park); 2014 Apr; 28(4):326-34. PubMed ID: 24839807 [TBL] [Abstract][Full Text] [Related]
2. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. Camicia R; Winkler HC; Hassa PO Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227 [TBL] [Abstract][Full Text] [Related]
3. Precision treatment of distinct molecular subtypes of diffuse large B-cell lymphoma: ascribing treatment based on the molecular phenotype. Dunleavy K; Roschewski M; Wilson WH Clin Cancer Res; 2014 Oct; 20(20):5182-93. PubMed ID: 25320368 [TBL] [Abstract][Full Text] [Related]
4. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. Schmitz R; Wright GW; Huang DW; Johnson CA; Phelan JD; Wang JQ; Roulland S; Kasbekar M; Young RM; Shaffer AL; Hodson DJ; Xiao W; Yu X; Yang Y; Zhao H; Xu W; Liu X; Zhou B; Du W; Chan WC; Jaffe ES; Gascoyne RD; Connors JM; Campo E; Lopez-Guillermo A; Rosenwald A; Ott G; Delabie J; Rimsza LM; Tay Kuang Wei K; Zelenetz AD; Leonard JP; Bartlett NL; Tran B; Shetty J; Zhao Y; Soppet DR; Pittaluga S; Wilson WH; Staudt LM N Engl J Med; 2018 Apr; 378(15):1396-1407. PubMed ID: 29641966 [TBL] [Abstract][Full Text] [Related]
5. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Lenz G; Wright GW; Emre NC; Kohlhammer H; Dave SS; Davis RE; Carty S; Lam LT; Shaffer AL; Xiao W; Powell J; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Campo E; Jaffe ES; Delabie J; Smeland EB; Rimsza LM; Fisher RI; Weisenburger DD; Chan WC; Staudt LM Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13520-5. PubMed ID: 18765795 [TBL] [Abstract][Full Text] [Related]
6. ABC, GCB, and Double-Hit Diffuse Large B-Cell Lymphoma: Does Subtype Make a Difference in Therapy Selection? Nowakowski GS; Czuczman MS Am Soc Clin Oncol Educ Book; 2015; ():e449-57. PubMed ID: 25993209 [TBL] [Abstract][Full Text] [Related]
7. Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment? Abramson JS Cancer; 2019 Sep; 125(18):3111-3120. PubMed ID: 31287161 [TBL] [Abstract][Full Text] [Related]
8. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Dunleavy K; Pittaluga S; Czuczman MS; Dave SS; Wright G; Grant N; Shovlin M; Jaffe ES; Janik JE; Staudt LM; Wilson WH Blood; 2009 Jun; 113(24):6069-76. PubMed ID: 19380866 [TBL] [Abstract][Full Text] [Related]
9. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Choi WW; Weisenburger DD; Greiner TC; Piris MA; Banham AH; Delabie J; Braziel RM; Geng H; Iqbal J; Lenz G; Vose JM; Hans CP; Fu K; Smith LM; Li M; Liu Z; Gascoyne RD; Rosenwald A; Ott G; Rimsza LM; Campo E; Jaffe ES; Jaye DL; Staudt LM; Chan WC Clin Cancer Res; 2009 Sep; 15(17):5494-502. PubMed ID: 19706817 [TBL] [Abstract][Full Text] [Related]
10. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma. Zhou M; Zhao H; Xu W; Bao S; Cheng L; Sun J Mol Cancer; 2017 Jan; 16(1):16. PubMed ID: 28103885 [TBL] [Abstract][Full Text] [Related]
11. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Hu S; Xu-Monette ZY; Balasubramanyam A; Manyam GC; Visco C; Tzankov A; Liu WM; Miranda RN; Zhang L; Montes-Moreno S; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Han van Krieken J; Huang Q; Huh J; Ai W; Ponzoni M; Ferreri AJ; Zhao X; Winter JN; Zhang M; Li L; Møller MB; Piris MA; Li Y; Go RS; Wu L; Medeiros LJ; Young KH Blood; 2013 Apr; 121(14):2715-24. PubMed ID: 23343832 [TBL] [Abstract][Full Text] [Related]
12. Machine learning-based classification of diffuse large B-cell lymphoma patients by eight gene expression profiles. Zhao S; Dong X; Shen W; Ye Z; Xiang R Cancer Med; 2016 May; 5(5):837-52. PubMed ID: 26869285 [TBL] [Abstract][Full Text] [Related]
14. The significance of FOXP1 in diffuse large B-cell lymphoma. Gascoyne DM; Banham AH Leuk Lymphoma; 2017 May; 58(5):1037-1051. PubMed ID: 27678023 [TBL] [Abstract][Full Text] [Related]
15. Is now the time for molecular driven therapy for diffuse large B-cell lymphoma? Di Rocco A; De Angelis F; Ansuinelli M; Foà R; Martelli M Expert Rev Hematol; 2017 Sep; 10(9):761-774. PubMed ID: 28712322 [TBL] [Abstract][Full Text] [Related]
16. Frontline treatment of diffuse large B-cell lymphoma: Beyond R-CHOP. Mondello P; Mian M Hematol Oncol; 2019 Oct; 37(4):333-344. PubMed ID: 30938848 [TBL] [Abstract][Full Text] [Related]
17. Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma. Dunleavy K; Erdmann T; Lenz G Cancer Treat Rev; 2018 Apr; 65():41-46. PubMed ID: 29549872 [TBL] [Abstract][Full Text] [Related]